Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
Doctors and hospitals must stop being bystanders to food-related illness and begin to become role models and educators in the transition to healthful eating habits, just as they did in tobacco cessation.
Until healthful food is widely affordable and accessible to all people, any discussions of how policy might infringe on the right to choose may be misguided.
A new Virginia law governing collaborations between nurse practitioners and doctors leaves unresolved key legal issues in team-based care, including those pertaining to medical malpractice and liability and anticompetitive practices.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Jalayne J. Arias, JD, MA and Kathryn L. Weise, MD, MA
Even when external factors such as nonaccidental injury weigh heavily on clinicians' perceptions, they should not lose focus on the patient's best interest when deciding whether to continue or withdraw treatment.
Jessie Kimbrough-Sugick, MD, MPH, Jessica Holzer, MA, and Eric B. Bass, MD, MPH
Researchers who approach community partners with an agenda already in hand are missing the point of the community-based participatory research enterprise: developing priorities for study together.
By privileging traditional research methods in forms for research protocol approval, IRBs can unknowingly allow community partners to be harmed in CBPR. Changes to the language can help ensure appropriate sensitivity and community involvement.